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ABSTRACT 
Staphylococcus aureus is a versatile human pathogen causing a wide range of diseases 
from uncomplicated skin and soft tissue infections to life-threatening invasive diseases like 
endocarditis, bacteremia, necrotizing pneumonia, and fasciitis. The pathogen has become 
increasingly resistant to -lactam antibiotics, and of special concern is the rise in community-
acquired (CA)-MRSA strains, as specific CA-MRSA clones have been associated with highly 
aggressive infections. The ability of S. aureus to cause such a multitude of infections is 
linked to the production of a wide array of virulence factors. Several virulence factors have 
been implicated in disease pathogenesis, including the exotoxins Panton-Valentine 
Leukocidin (PVL), alpha-toxin (α-toxin), superantigens and phenol soluble modulins. This 
thesis project aimed to characterize S. aureus strains in the community as well as through 
use of clinical invasive isolates and human lung/skin organotypic tissue models explore the 
role of specific staphylococcal toxins and virulence regulation in the pathologic events 
leading to the destructive infections in lung and skin. 
In paper I, molecular characterization of Indian community S. aureus isolates to determine 
their lineage and to analyze their virulence and immune-evasion factors was conducted. The 
percentage of methicillin resistance was 26% in carrier isolates while 60% among disease 
isolates. 69% of the isolates were positive for PVL genes along with combinations of many 
other toxins. The patterns of presence and absence of virulence and immune evasion factors 
strictly followed the sequence type (ST). We are reporting several new STs, which have not 
been reported earlier, along with factors influencing virulence and host-pathogen 
interactions. Next, we demonstrate in paper II that community S. aureus strains displayed 
stable phenotypic response profiles, defined by either proliferative or cytotoxic responses. 
The cytotoxic supernatants contained significantly higher levels of α-toxin as compared to 
proliferative supernatants. Furthermore, a significant association between agr type and 
phenotypic response profile was found, with agr I and agr IV strains being predominantly 
cytotoxic whereas agr II and III strains were proliferative. This differential response profiles 
associated with certain S. aureus strains with varying toxin production abilities could have an 
impact on disease outcome and may reflect upon the existence of specific pathotypes. 
In paper III we focused on the pathogenesis of CA S. aureus severe pneumonia, in 
particular, the impact of exotoxins produced by strains isolated from varying severity of lung 
infections on human host cells and in human 3D organotypic lung tissue. α-toxin had a direct 
damaging effect on the epithelium whereas PVL contributed indirectly to the tissue pathology 
by triggering lysis of neutrophils. We demonstrated that severe tissue pathology is 
associated with a combination and high levels of both α-toxin and PVL, and fatal outcome 
correlated with higher toxin production in pneumonia. Notably, both α-toxin and PVL 
mediated cytotoxic effect and epithelial disruption was significantly abrogated by addition of 
polyclonal intravenous immunoglobulins. 
In paper IV we focused on skin and soft tissue infections caused by ST22 strains, one of the 
most critically expanding MRSA clones world-wide. Here we identified a mechanism for 
which new variants, cytotoxic vs. persistent phenotype, can emerge. We link this phenotype 
switch to a specific mutation of receptor histidine kinase AgrC. The phenotypic switch to a 
persistence phenotype is associated with upregulation of bacterial surface proteins, less 
severe skin tissue damage, resistance to antimicrobials, and induction of autophagy. In 
contrast, cytotoxic phenotype strains showed upregulated exotoxin expression and caused 
infections characterized by inflammasome activation and severe skin tissue pathology. This 
study shows a strong effect of a single amino acid substitution in AgrC as a critical factor 
contributing to virulence properties and infection outcome. 
Together, the studies in this thesis demonstrate that several different toxins will contribute to 
tissue pathology, but they target different cells and their impact may be tissue-specific. Also, 
distinct functional differences between the isolates were identified that are likely to contribute 
to disease outcome. Such insight should promote the development of novel diagnostics or 
therapeutic strategies. 
  
LIST OF SCIENTIFIC PAPERS 
This thesis is based on three publications and one manuscript. The individual papers are 
referred to by roman numerals 
I. Shambat S, Nadig S, Prabhakara S, Bes M, Etienne J and Arakere G. 
Clonal Complexes and virulence factors of Indian Staphylococcus aureus
from the Community. BMC Microbiology, (2012) 12:64. doi: 10.1186/1471-
2180-12-64. 
 
II. Mairpady Shambat S, Haggar A, Vandenesch F, Lina G, van Wamel WJB, 
Arakere G, Svensson M, Norrby-Teglund A. Levels of Alpha-Toxin 
Correlate with Distinct Phenotypic Response Profiles of Blood Mononuclear
Cells and with agr Background of Community-Associated Staphylococcus 
aureus Isolates. PLoS One, (2014) 9(8): e106107.  
doi: 10.1371/journal.pone.0106107 
 
III. Mairpady Shambat S, Chen P, Nguyen Hoang A.T,  Bergsten H,
Vandenesch F, Siemens N,  Lina G,  Monk I.R, Foster T.J, Arakere G,
Svensson M*, and Norrby-Teglund A.* Modelling staphylococcal 
pneumonia in a human 3D lung tissue model system delineates toxin-
mediated pathology. Disease Models and Mechanisms, (2015)  8: 1413-
1425. doi: 10.1242/dmm.021923. 
 
IV. Mairpady Shambat S*, Siemens N *, Monk I.R, Mohan B. D, Mukundan S,
Krishnan K C, Prabhakara S, Snäll J , Kearns A, Vandenesch F, Svensson 
M, Kotb M, Gopal B, Arakere G, and Norrby-Teglund A. A phenotype switch 
in the successful MRSA ST22 clone dictates infection outcome.  
* Equal contribution, Submitted Manuscript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ADDITIONAL PAPERS 
 
 Prabhakara S, Khedkar S, Mairpady Shambat S, Srinivasan R, Basu
A, Norrby-Teglund A, Narain Seshasayee A S, Arakere G. Genome
Sequencing Unveils a Novel Sea Enterotoxin-Carrying PVL Phage in
Staphylococcus aureus ST772 from India. PLoS One, (2013)
8(3):e60013.  doi: 10.1371/journal.pone.0060013. 
 
 Siemens N, Chakrakodi B, Mairpady Shambat S, Morgan M,
Bergsten H, Hyldegaard O, Skrede S, Arnell P, Johansson L,
INFECT Study Group, Juarez J, Bosnjak L, Mörgelin M, Svensson
M*, and Norrby-Teglund A*. Biofilm in group A streptococcal
necrotizing soft tissue infections (Submitted; Under review). 
 
 
  
CONTENTS 
1 INTRODUCTION .......................................................................................................... 1 
1.1 Staphylococcus aureus ................................................................................... 1 
1.1.1 Epidemiology ........................................................................................... 1 
1.1.2 Molecular Typing of Staphylococcus aureus .......................................... 2 
1.1.3 Hospital-Associated Methicillin-Resistant Staphylococcus aureus ........ 4 
1.1.4 Community-Associated Methicillin-Resistant Staphylococcus 
aureus ..................................................................................................... 4 
1.1.5 Pulmonary Infections .............................................................................. 5 
1.1.6 Skin and Soft Tissue Infections .............................................................. 7 
1.2 Virulence Factors .............................................................................................. 7 
1.2.1 α-toxin ...................................................................................................... 8 
1.2.2 Bicomponent Pore-Forming Leucocidins ............................................... 9 
1.2.3 Phenol-Soluble Modulins ...................................................................... 11 
1.2.4 Superantigens ....................................................................................... 12 
1.2.5 Staphylococcal Protein A ...................................................................... 12 
1.3 The Agr System ............................................................................................... 13 
1.4 Host-Pathogen Interactions ........................................................................... 15 
1.4.1 S. aureus and Airway Epithelial Response .......................................... 16 
1.4.2 S. aureus and Skin ................................................................................ 18 
1.4.3 S. aureus and Neutrophils .................................................................... 19 
2 AIMS ........................................................................................................................... 21 
3 METHODOLOGY ....................................................................................................... 22 
4 RESULTS AND DISCUSSION .................................................................................. 25 
4.1 Molecular characterization of Staphylococcus aureus strains from 
the community ................................................................................................. 25 
4.1.1 Antibiotic Resistance ............................................................................. 25 
4.1.2 Major MLST types and their virulence gene profile .............................. 26 
4.2 Community S. aureus elicits stable cytotoxic or proliferative 
responses in human PBMC: Link to agr type and alpha-toxin levels ...... 27 
4.2.1 Functional properties of clinical S. aureus isolates: proliferative or 
cytotoxic profiles .................................................................................... 28 
4.2.2 Significant association between agr type and proliferative or 
cytotoxic profile ..................................................................................... 29 
4.2.3 α-toxin expression correlates with cytotoxicity against PBMC ............. 29 
4.3 Toxin-mediated pathology in a humanized lung tissue model 
exposed to S. aureus toxins .......................................................................... 30 
4.3.1 Necrotizing pneumonia isolates mediated strong cytotoxicity and 
increased tissue disruption ................................................................... 31 
4.3.2 α-toxin and PVL mediated cell-specific cytotoxicity contributes 
towards epithelial damage .................................................................... 32 
4.3.3 Augmented inflammation, tissue necrosis and chemotactic 
responses induced by S. aureus toxins in lung tissue model. ............. 34 
4.4 Phenotype switch in S. aureus ST22 strains causing skin infections 
is regulated by a point mutation of receptor histidine kinase AgrC ........ 35 
4.4.1 Distinct phenotypical profiles of ST22 strains due to a single point 
mutation in agrC.................................................................................... 36 
4.4.2 Cytotoxic vs persistence phenotype in a human 3D skin model ......... 37 
5 CONCLUDING REMARKS AND FUTURE ASPECTS ............................................ 40 
6 ACKNOWLEDGEMENTS ......................................................................................... 42 
7 REFERENCES ........................................................................................................... 45 
 
  
  
LIST OF ABBREVIATIONS 
MRSA methicillin-resistant S. aureus 
MSSA methicillin-susceptible S. aureus 
CA-SA community-acquired S. aureus 
MLST 
PFGE 
ST 
CC 
SPA 
SCCmec 
PBP2a 
MIC 
UTI 
SSTIs 
MGEs 
Agr 
ADAM10 
PVL 
GPCRs 
TLR 
HlgAB/HlgCB 
PSMs 
Hld 
FPR2 
DCs 
SAgs 
SEls 
TSST-1 
APCs 
AIP 
PAMPs 
NLRs 
SCIN 
multilocus sequence typing 
pulsed-field gel electrophoresis 
sequence type 
clonal complexes 
Staphylococcal protein A 
staphylococcal cassette chromosome mec 
penicillin binding protein 2a 
minimum inhibitory concentration 
urinary tract infections 
skin and soft tissue infections 
mobile genetic elements 
accessory gene regulator 
A Disintegrin and Metalloprotease 10 
Panton-Valentine leucocidin 
G-protein-coupled receptors 
Toll-like receptors  
Gamma-hemolysin 
Phenol soluble modulins 
-hemolysin 
N-formyl-peptide receptor 2 
Dendritic cells 
Staphylococcal superantigens 
staphylococcal enterotoxin-like toxins 
toxic shock-syndrome toxin 1 
antigen presenting cells 
auto inducing peptide 
pathogen-associated molecular patterns 
nod-like receptors 
staphylococcal complement inhibitor 
CHIPS 
LTA 
MSCRAMMs 
LFA-1 
ICAM 
Efb 
Ecb 
Sbi 
PBMC 
 
 
chemotaxis inhibitory protein of staphylococci 
Lipoteichoic acid 
microbial surface components recognizing adhesive matrix molecule 
lymphocyte function associated antigen-1 
intracellular adhesion molecules 
extracellular fibrinogen-binding protein 
extracellular complement-binding protein 
second binding protein of immunoglobulin 
peripheral blood mononuclear cells 
 
 
 
 
  1 
1 INTRODUCTION 
1.1 STAPHYLOCOCCUS AUREUS 
Staphylococcus aureus is a gram-positive, non-motile, and a common commensal of 
humans. It stably colonizes the nares, axillae, the skin, and can be present persistently 
among approximately one-third of the human population, whereas another one-third of the 
population are colonized intermittently (1-3). S. aureus was first isolated from the surgical 
wounds in 1882 by the Scottish surgeon Sir Alexander Ogston (4). Based on its appearance 
it was classified as Staphylococcus (from the Greek staphylos [“grape”] and kokkos [“berry” 
or “seed”]) (5). Later, after a couple of year’s German physician; Friedrich J. Rosenbach 
described pigmented colonies of staphylococci isolated from humans and proposed the 
nomenclature Staphylococcus aureus (from the Latin aurum [“gold”]). The golden yellow 
pigmentation of the colonies is due to a membrane-bound carotenoid called staphyloxanthin, 
which protects S. aureus from reactive oxygen species and phagocytic killing (6). S. aureus 
is a significant cause of human infections globally. It can cause a wide variety of infections 
ranging from minor skin infections to fatal necrotizing pneumonia or necrotizing fasciitis as 
well as bloodstream infections leading to severe disease manifestations such as sepsis, 
infective endocarditis, and deep-seated abscesses. Apart from that it is also estimated that 
30–35% of healthy human individuals carry S. aureus on the skin or nasal nares (7, 8). 
The pathogen has become increasingly resistant to -lactam antibiotics and methicillin-
resistant S. aureus (MRSA), which are resistant to all available penicillin’s and other -
lactam antimicrobial drugs, is now a leading cause of hospital-acquired infections (9-11) 
MRSA infections are associated with greater lengths of hospital stay, higher mortality and 
increased costs than infections caused by methicillin-susceptible S. aureus (MSSA) (12). In 
the US, S. aureus infection is among the leading causes of death by any single infectious 
agent (13). S. aureus is the most frequently occurring pathogen in hospitals and the second 
most common pathogen in outpatient (14). Despite substantial advances in health care as 
well as medical treatment, the morbidity and mortality caused by S. aureus is still 
continuously increasing. In addition and of special concern is the rise in community-acquired 
S. aureus (CA-SA) strains, as specific CA-MRSA clones are associated with highly 
aggressive infections, including severe skin and soft tissue infections, necrotizing fasciitis 
and necrotizing pneumonia, in otherwise healthy individuals.  
1.1.1 Epidemiology 
S. aureus is one of the most commonly occurring pathogen in hospitals and long-term 
hospital stay is related to an increasing morbidity and mortality due to infection. 
Approximately 400,000 cases of S. aureus infections are reported per year between 2003-
2005 in the USA alone (15) and MRSA infections kill approximately 20,000 hospitalized 
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American patients each year (13). Taken together with the fact that (a) antibiotics is as a 
strong driver for resistance, (b) there is a rampant antibiotic consumption in many developing 
countries where MRSA is hyper endemic, and (c) the striking intercontinental spread of 
virulent MRSA clones, MRSA strains being pandemic, with dissemination of specific HA-
MRSA clones from the 1960s, CA-MRSA clones from the 1990s, it is obvious that MRSA 
represent a significant health threat for both developing and developed countries. Till few 
years ago, the distinction between hospital associated methicillin-resistant S. aureus (HA-
MRSA) and CA-MRSA was clear. CA-MRSA strains had distinctly different antibiotic 
sensitivities with low MIC values for oxacillin or imipenem as compared to HA-MRSA 
infected patients (16). But in the last 5 to 7 years, CA-MRSA has infiltrated the hospitals and 
is replacing HA-MRSA, mainly in countries where CA-MRSA is highly prevalent (17, 18). The 
morbidity and high mortality of these infections, together with a rapid rise in the incidence of 
CA-MRSA world-wide, suggest that some CA-MRSA strains are more virulent and 
transmissible than are traditional HA-MRSA strains. Although the increase in CA-MRSA 
infection has been well recognized, few studies have focused on the current 
epidemiological status of CA-MSSA strains. Most of the MSSA clones are identified as 
being Panton-Valentine Leukocidin (PVL) positive and belong to more diverse genetic 
backgrounds as compared to MRSA strains (14). A study conducted by McCaskill et. al. 
between 2001 and 2006 in Texas children hospital demonstrated an increase in the 
proportion of CA-MSSA infections (19). Similarly, a recent prospective study comparing the 
characteristics and outcomes of PVL positive MRSA and PVL positive MSSA in 
pneumonia cases demonstrated that methicillin resistance is not associated with severity 
of S. aureus pneumonia (20). Since CA-MSSA strains are most plausible reservoirs of CA-
MRSA further epidemiological surveillance studies and infection control efforts focusing 
MSSA strains as well must be reinforced (14).  
1.1.2 Molecular Typing of Staphylococcus aureus 
An important tool for understanding the nomenclature and epidemiology of these globally 
distributed strains is molecular typing to determine clonality of strains. The current 
nomenclature of S. aureus is mainly based on various methods of molecular genotyping 
techniques that are being used. Presently there are four primary methods that are widely 
recognized for typing S. aureus strains i.e. multilocus sequence typing (MLST), pulsed-field 
gel electrophoresis (PFGE), spa typing, and SCCmec typing (21, 22). MLST is based on 
sequencing of fragments of seven specific housekeeping genes (arc, aroE, glpF, gmk, pta, 
tpi, yqiL). Sequence variations among each individual genes are given different allele 
numbers, and all the seven alleles are linked together to form a unique allelic profile called 
sequence type (ST). Related ST types sharing at least five out of the seven alleles are 
grouped into single clonal complexes (CC) (22). 
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PFGE is a kind of fingerprinting method wherein whole genomic DNA of S. aureus is 
digested using a restriction enzyme called SmaI. This creates a banding pattern based on 
the size of each digested fragment in a matrix gel. This method is highly used in 
investigations of outbreaks involving closely related S. aureus strains (22). 
Spa typing is also a sequencing based method wherein the highly polymorphic variable 
region of Staphylococcal protein A (spA) gene consisting of number of tandem repeats, 
typically 24 bp in length are sequenced. These duplicating repeats contribute towards a 
unique pattern called spa types. 
Almost all MRSA strains carry SCCmec elements which include mecA gene encoding for 
penicillin-binding protein 2a (PBP2a) contributing towards the methicillin resistance (23). The 
mecA gene is found integrated into a specific chromosomal region called the orfx by 
horizontal gene transfer and hence is called staphylococcal cassette chromosome mec 
(SCCmec) (24). Based on their structural organization and genetic content SCCmec element 
type I-XI are identified, which are mainly distinguished by the type of ccr gene complex that 
mediates the site-specific excision and insertion and the class of mec complex that they bear 
(25). Conventionally HA-MRSA strains are found to usually carry large SCCmec types I, II, 
or III, while CA-MRSA strains are usually characterized by the possession of smaller 
SCCmec types IV and V (Figure 1) (26). 
 
Figure 1: Classification of SCCmec type based on ccr complex and mec complex type. Adapted and 
modified from (12) 
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1.1.3 Hospital-Associated Methicillin-Resistant Staphylococcus aureus 
MRSA strains that are circulating in the hospital settings are classified as HA-MRSA and are 
mostly responsible for invasive MRSA infections. HA-MRSA is highly prevalent worldwide 
with North and South America demonstrating high rates (>50%), while in other parts such as 
Asia, Australia, Africa and some European countries  intermediate rates of around 25-50% 
are reported. The lowest prevalence of HA-MRSA strains are generally seen in Netherlands 
and Scandinavian countries (27, 28). The most common and frequently reported genotypes 
of HA-MRSA strains are CC5, CC8, CC22, CC30, and CC45 (7, 29, 30). Strains belonging 
to CC22 and CC30 type are widespread globally, whereas CC45 is commonly found in USA 
and Europe (7, 17) and strains from CC8 and CC5 are frequently isolated in Asia (Figure 2) 
(31). 
 
Figure 2: Global distribution of major MRSA lineages by sequence type  
1.1.4 Community-Associated Methicillin-Resistant Staphylococcus aureus 
CA-MRSA has become a widespread problem in many developed as well as developing 
countries around the world during the last decades (8, 12). The definition for CA-MRSA 
infection is based on several clinical and bacteriological criteria i.e. (i) MRSA infection 
diagnosed for an outpatient or within 48 h of hospitalization, (ii) patients lacking the following 
HA-MRSA risk factors including hemodialysis, surgery, residence in a long-term care facility 
or hospitalization during the previous year, the presence of an indwelling catheter or a 
percutaneous device at the time of culture, or previous isolation of MRSA from the patients 
(32), and (iii) CA-MRSA strains differ from HA-MRSA strains in their molecular 
characteristics (8, 12) carrying specific antibiotic cassette such as  SCCmec IV or SCCmec 
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V. Furthermore CA-MRSA strains commonly lack multiple antibiotic resistance genes, 
except to β-lactams antibiotics, and frequently have different exotoxin gene profiles, e.g. 
PVL, pathogenicity islands, ACME elements genes (Figure 3) (12, 33, 34). Various MRSA 
clones have spread between the community and hospitals, particularly CA-MRSA strains are 
being transmitted in the hospital settings and the circulation of HA-MRSA strains that occurs 
in the community makes the distinction between CA-MRSA and HA-MRSA very difficult (18). 
Studies of global transmission of CA-MRSA identified 5 major intercontinental pandemic 
MRSA clones, which were found to have evolved from 2 distinct evolutionary lineages (35). 
However, there is a striking geographic variation in predominant CA-MRSA clones with most 
cases in the US belonging to CC8 (USA300 and USA400), whereas in Europe ST80 is 
predominate and in Australia ST93 (Figure 2) (8). In Sweden, which is a low prevalence 
country, imported MRSA strains through travel and immigrations represent a large proportion 
of the cases and importantly, regions with the highest risk for MRSA in travelers showed a 
correlation with community-acquisition (36). CA-MRSA infections mainly occur in healthy 
young individuals, through skin-to-skin contact. The major clinical manifestation associated 
with CA-MRSA is skin and soft tissue infections (SSTIs) (about 70-80%), but severe life-
threatening infections such as necrotizing fasciitis, necrotizing pneumonia, and severe 
sepsis have also been reported (12, 37, 38). CA-MRSA strains also cause wound infection, 
surgical site infections, urinary tract infections (UTI), meningitis, sinusitis and eye infections 
(Figure 4) (39-41). 
 
Figure 3: Main characteristic features of CA-MRSA strains (12). 
1.1.5 Pulmonary Infections 
S. aureus is one of the major pathogens implicated in the development of pneumonia in both 
CA and HA infections including MSSA and MRSA (42-44). Traditionally, S. aureus accounts 
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for approximately one-third of pleural empyema cases (45) and these infections usually 
occur as a result of hematogenous spread or via local extension from other infected source 
(46). These respiratory infections lead to a wide range of outcomes, from asymptomatic 
colonization to fulminant invasive clinical outcome, and the host immune response plays a 
significant role in determining the consequence of these infections. Severe, invasive CA-
MRSA infections especially necrotizing pneumonia have a high mortality rate, even when 
optimal therapeutic treatments are used. It is a distinct syndrome characterized by a massive 
influx of neutrophils into the lung parenchyma, formation of abscesses, hemoptysis, high 
fever, and lung lesions, often requiring mechanical ventilation. Cases of necrotizing MRSA 
pneumonia are often associated with a prior respiratory viral infection, predominantly 
influenza (47) and occur most often in children, young adults and immunocompromised 
patients (48). Although the incidences of CA-pneumonia is fairly low (around 2 to 3% in the 
USA, around 10% in the United Kingdom and around 3% in Australia (Figure 4)) the rapid 
expansion of these community-acquired virulent and highly transmissible S. aureus strains is 
a major cause of concern. The emergence of severe necrotizing pneumonia is usually 
epidemiologically linked to infection with distinct CA-MRSA strains carrying genes for PVL. 
This association between S. aureus strains carrying genes for PVL and necrotizing 
pneumonia was first identified in USA (37) and then in France (49) followed by subsequent 
studies of community-associated pneumonia in otherwise healthy individuals (50, 51). 
Molecular epidemiological studies have identified a dominance of a few major clones of S. 
aureus strains wide spread throughout USA and Europe, and the mechanism for their 
success is attributed to their abilities to acquire genes of both antimicrobial resistance and 
virulence genes through horizontal gene transfer.  
 
Figure 4: Burden and infections caused by CA-S. aureus strains 
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1.1.6 Skin and Soft Tissue Infections 
CA-S. aureus strains are most commonly associated with SSTIs. Any breach in the skin 
barrier function that occurs due to a trauma, and/or surgical procedures can cause entry of 
S. aureus into the subcutaneous tissues. Apart from that S. aureus may also cause infection 
without any barrier breach including at hair follicles causing folliculitis, bullous or superficial 
lesions, confluent abscess like furuncles and carbuncles all such infections are classified as 
SSTIs (Figure 4) (12, 52). Over the past fifteen years, the emergence of CA-MRSA strains 
associated with SSTI infections has increased and it has become apparent that CA-MRSA 
epidemic is not only replacing the endemic SSTI strains but also increasing the burden of 
SSTIs (8, 53). The earliest cases reported of CA-MRSA strains causing SSTIs in USA was 
in the late 1990s and was mainly caused by USA400 strain type (54). Since the 2000s, it has 
been replaced predominantly by USA300 strain type contributing to more than 50% of the 
SSTI cases in the USA alone (55). Apart from that, a 3 fold increase in the admission rates 
for abscess and cellulitis is found in the United Kingdom, similarly in Australia, it was 
identified about 48% increase in cutaneous abscess as well as an increase in outpatients 
CA-MRSA strains attributed to SSTI (56, 57). Differential gene expression of virulence 
factors such as alpha-toxin (α-toxin), PVL, phenol soluble modulins (PSM), Staphylococcal 
Protein A (SPA), cell surface associated factors and ACME elements have contributed 
towards these enhanced virulence properties of CA-MRSA strains (Figure 3) (58). Similarly, 
PVL-positive CA-MRSA strains are isolated usually from deep-seated skin infections such as 
furuncle, carbuncle, and cellulitis (59), whereas superficial skin infections and impetigo are 
related to PVL-negative CA-MRSA strains (60). A study on nasal carriage of MRSA identified 
a correlation between nasal carriage and development of SSTI, suggesting that nasal 
carriage of MRSA strains can contribute towards the risk factor for SSTI (60). 
 
1.2 VIRULENCE FACTORS 
S. aureus express a wide array of virulence factors that enables its survival during infection. 
The ability to secrete a diverse repertoire of immune evasion factors, including cytotoxins 
(hemolysins, cytolytic peptides, leucocidins), immunomodulatory proteins (superantigens, 
complement-inhibitory proteins), and factors that prevent immune cell recognition (SPA, 
among others) contribute in various ways to disease pathogenesis (61, 62). The majority of 
these virulence factors is encoded on mobile genetic elements, such as plasmids or 
prophages, and is transferred between strains by horizontal gene transfer (53, 61). Each of 
these molecules destabilizes the host immune system in many different ways and mediates 
resistance mainly towards innate immune defenses. The expression of these virulence 
factors adds to the multi-faceted action triggering pathological immune response, support 
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bacterial proliferation and evade elimination in the host. Several of these toxins are specific 
towards human cells, indicating the longstanding adaptation of S. aureus as a human 
pathogen. 
1.2.1 α-toxin 
α-toxin is one of the major and by far the most carefully well examined secreted virulence 
factor of S. aureus. The majority of the strains produce α-toxin. The toxin is cytotoxic to a 
wide range of cell types particularly was initially described as exhibiting dermonecrotic and 
neurotoxic factor and has since been shown to be cytotoxic. The mature protein contains 
293 amino acid residues and has a molecular weight of 33 kDa, composed of beta-sheets 
(65%) and alpha-helical structures (10%). The production of α-toxin is under the control of 
the global accessory gene regulator (agr) (63) and it is produced during the late exponential 
growth phase of bacterial culture. The expression of α-toxin is found to be increased upon 
interaction with epithelial cells (64-66) and correlates with the virulence of S. aureus strains 
(67, 68). It is produced as monomeric component and these secreted monomers integrate 
into the membrane of target cells and form cylindrical heptamers (Figure 5) (69). This 
binding usually occurs in two different ways. At higher concentrations, α-toxin nonspecifically 
adheres to the cell membrane (70) and this oligomeric form induces lyses of eukaryotic cells. 
However at low concentrations, A Disintegrin and Metalloprotease 10 (ADAM10) is involved 
as a specific receptor for α-toxin (71). The species and cellular specificity exhibited by α-
toxin correlate with ADAM10 expression (71). Interaction of α-toxin with both membrane 
lipids and its cell surface receptor indicates the cooperative nature of these interfaces in the 
modulation of toxin binding, assembly, and cytotoxicity (Figure 5). The α-toxin binding to 
ADAM10 at the cell surface induces the metalloprotease catalytic activity resulting in 
cleavage of E-cadherin (71, 72). This, in turn, causes loss of interaction between adjacent 
cells at the adherens junction, thereby disrupting the epithelial barrier function. Pore 
formation by the toxin triggers rapid release of ATP, K+ ions and influx of extracellular 
calcium into the cell, results in leaky gaps between cells leading to apoptotic cell death (73). 
In addition, α-toxin generate a chemokine gradient that facilitates neutrophil and other 
immune cell recruitment in the lung (74), and it induces inflammatory responses in multiple 
cell types resulting in the release of cytokines and pro-inflammatory mediators (75, 76). 
Intoxication with α-toxin triggers (NLRP3) inflammasome, caspase-1 activation and induces 
IL-1β secretion in macrophages and monocytes. (Figure 6) (77, 78). These inflammatory 
stimuli, associated cell death via pyroptosis, exert a deleterious effect on the local tissue 
microenvironment, increasing the reactivity of the vasculature, promoting tissue edema, and 
modulating host immunity. Due to its important role in pathogenesis, α-toxin has been an 
active focus of vaccine development. Toxin antibodies have shown protective role in mice 
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(79) and rabbits (80, 81) models of pneumonia. Furthermore, structural analogues of α-toxin 
have been shown to reduce epithelial damage in S. aureus pneumonia (82, 83).  
 
Figure 5: Cell specificities and receptor mediated targeting of S. aureus cytotoxins (84-86) 
1.2.2 Bicomponent Pore-Forming Leucocidins  
The bicomponent leucocidins produced by S. aureus are capable of exerting a potent lytic 
activity on a variety of host immune cells of the myeloid lineage, namely monocytes, 
macrophages, and neutrophils. Van de Velde in his studies first demonstrated leukocidal 
activity of S. aureus and over the past 100 years research has advanced from that of a 
single lytic toxin molecule to the identification of six different leucocidins (HlgAB, HlgCB, 
LukAB, PVL, LukED and LukMF) (87). The first pore-forming leucocidin to be purified from S. 
aureus was PVL. It consists of two subunits designated as S (slow; LukS-PV), and the other 
as F (fast; LukF-PV), based on their elution profiles (88-90). These bicomponent toxins are 
cytotoxic only when both the subunits are combined and cytolytic activity requires; (i) each of 
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the monomeric subunits (S and F) are secreted; (ii) initially S subunit recognizes proteins 
and/or lipids on the host surface in a species- and cell type-specific manner, followed by F 
subunit recruitment and recognizing each other; (iii) the subunits accumulate into an 
octameric structure with alternating F and S components forming a prepore. Furthermore, 
the stem domains unfold causing structural shifts and insert into the cell membrane to form 
pore formation (Figure 5) (91, 92). PVL is encoded within a lysogenic temperate phage 
φSLT (93, 94). The lukS-PV gene encodes a 312-amino-acid protein with a molecular weight 
of 32kDa similarly LukF-PV protein is a 325 amino-acid protein with a molecular weight of 
34kDa (95). The leucocidin gene is regulated by a number of master regulators and external 
signals provide major inputs into their altered gene expression. Under favorable 
environmental conditions, Agr-mediated RNAIII negatively regulates the leucocidin repressor 
Rot inducing increased production of leucocidins especially PVL (85). Similarly, SarA 
indirectly facilitates leucocidin expression by positively regulating the expression of RNAIII. 
Upon external stimuli, SaeRS two-component system induces direct binding of SaeR to 
leucocidin promoters and inducing its production (85). PVL is present in only approximately 2 
to 5% of all S. aureus isolates it received a lot of attention as specific PVL-positive CA-
MRSA types (such as USA300) were epidemiologically linked to the emergence of severe 
necrotizing infections in particular necrotizing pneumonia (96, 97). Although compelling 
epidemiological data, direct evidence for a role of PVL as a virulence determinant was 
sought through experimental murine models of acute pneumonia, soft tissue or sepsis. 
Isogenic PVL-positive and PVL-negative S. aureus strains were used in these animal studies 
and provided conflicting results (67, 98). The role of PVL in staphylococcal virulence and 
disease has since been greatly debated. Recent studies have emphasized the importance of 
host susceptibility to PVL with a strong and rapid cytotoxic activity against neutrophils 
isolated from human, but not from murine or non-human primates (99). A role for PVL was 
then further substantiated in a rabbit model of necrotizing pneumonia in which PVL 
significantly enhanced the tissue injury, inflammation, and death of the animals (100). The 
transmembrane G-protein-coupled receptors (GPCRs) C5aR and C5L2 were recently 
identified as the cellular receptors of PVL (101). The recognition by PVL is mediated by both 
the core membrane-spanning portions as well as their extracellular N-terminal region (101). 
PVL “S” subunit is highly specific against human cells expressing C5aR especially 
neutrophils, while less specific against murine and macaque cells (Figure 6). The binding of 
LukS-PV to C5aR not only exerts cytotoxic effect but also induces priming and activation of 
neutrophils promoting proinflammatory responses (Figure 6) (102, 103). The cytotoxic effect 
of PVL leads to the release of proinflammatory mediators such as IL-8 and also induces 
substantial cellular damage by the release of tissue-damaging enzymes. At sublytic 
concentrations PVL (i) induces granule exocytosis and increased bactericidal property of 
neutrophils (Figure 6) (85), (ii) triggers (NLRP3) inflammasome, (iii) induces IL-1β secretion 
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mediated by potassium efflux, (iv) causes NF-κB activation as a result of calcium influx and 
by engaging Toll-like receptors (TLR2 and TLR4) and (v) apoptosis due to mitochondrial 
disruption (Figure 6) (85).  
Gamma-hemolysin (HlgAB/HlgCB) is encoded in the core genome; both share the same F 
subunit (HlgB), but differ in their S subunit (HlgA and HlgC) and are expressed by 99% of S. 
aureus strains (Figure 5) (104, 105). These leucocidins are cytotoxic towards red blood cells 
and are usually found upregulated during blood stream infection (106). HlgCB also targets 
the same C5aR as that of PVL to exert cytotoxic effect against neutrophils and macrophages 
(Figure 6) (107). Similarly CXCR1, CXCR2, and CCR2 are identified as the cellular receptors 
of HlgAB (Figure 6) (107).  
LukED is the one and only leucocidin which exhibits broad activity on different cell types as 
well as from different species (85). LukED is found to be lineage specific in its gene 
expression and is present in approximately around 70% of S. aureus strains (Figure 5) (108, 
109). LukED targets CCR5 as its cellular receptor to lyse macrophages, T cells and dendritic 
cells (Figure 6) (110). Similarly chemokine receptors CXCR1 and 2 are utilized to exert its 
cytotoxic effect towards neutrophils, monocytes and NK cells (Figure 6) (111). 
LukAB is the most recently identified S. aureus leukotoxin (112, 113) and is the only 
leukotoxin that is found to be secreted as well as cell surface associated (113). Human 
CD11b a component of the integrin Mac-1 is required by LukAB to exert cytotoxicity towards 
neutrophils, macrophages, and monocytes and determines its cell and species specificity 
(114).  This leukotoxin also enhances S. aureus intracellular survival and facilitate escape 
upon phagocytosis by human neutrophils. 
1.2.3 Phenol-Soluble Modulins  
PSMs are a family of small amphipathic -helical peptides broadly divided into two 
subfamilies, (i) PSMincluding -hemolysin (Hld) being short around 20-26 amino acids long 
and  (ii) PSMwhich are long 40-44 amino acids in length (65). PSMs are core genome-
encoded genes at three different locations, PSM- PSMwithin the psmα operon PSMβ1 
- PSMβ2 within the psmβ operon and -hemolysin encoded within the RNAIII of the agr 
system. The PSMs are regulated by the agr system independent of the RNAIII mediated 
regulation (115) and also influence the expression α-toxin (116). The production of PSMs 
correlates with the capacity of S. aureus strains to cause invasive infections (117) and CA-
MRSA strains usually show an increased production of PSMs as compared to HA-MRSA 
(118). PSM peptides especially PSMeffectively lyse human leukocytes and erythrocytes 
(118) and also they facilitate neutrophil killing upon phagocytosis (119, 120), mainly 
mediated by strong expression of agr regulating the PSMs production within neutrophil 
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phagosome (121). PSMs are sensed by leukocytes via N-formyl-peptide receptor 2 (FPR2) 
which leads to pro-inflammatory responses, including the release of IL-8, recruitment of 
neutrophils, activation, and lysis of neutrophils and DCs (118, 122) contributing to 
inflammation and severity of tissue injury. 
1.2.4 Superantigens  
Staphylococcal superantigens (SAgs) are secreted toxins which act as a potent T cell-
mitogen and can activate or stimulate T cells at very low concentrations. The staphylococcal 
SAgs are basically divided into three different subclasses (i) staphylococcal enterotoxins 
(SEs); (ii) staphylococcal enterotoxin-like toxins (SEls); and (iii) toxic-shock-syndrome toxin 
1(TSST-1) (123). Till now 24 different staphylococcal SAgs have been identified of which 12 
are enterotoxins; 11 enterotoxin-like proteins and finally TSST-1 (124). S. aureus isolates 
exhibit a high heterogeneity in terms of carrying SAg genes, as they are encoded on mobile 
genetic elements, such as bacteriophages, plasmids, and pathogenic genomic islands. 80% 
of the strains express genes for around five to six different SAgs (125) and their expression 
is regulated by four different global regulators such as Agr, SarA, SarB and SaeRS (125). 
The hallmark of SAgs is that they activate and stimulate a large fraction of T cells by directly 
cross-linking without prior processing certain TCR Vdomains with conserved structures on 
MHC class II molecules expressed on professional APCs resulting in massive proliferation of 
T cells, cytokine production and apoptosis (Figure 6) (126). TSST-1 causes toxic shock 
syndrome (TSS) defined by high fever, rash, desquamation, vomiting, diarrhea, and 
hypotension, frequently resulting in multiple organ failures. Similarly, enterotoxins (SEA and 
SEB) are shown to play a major role in skin (atopic dermatitis) and airway (asthma) allergies 
by modulating the levels of IgE antibodies (95, 127, 128).  
1.2.5 Staphylococcal Protein A  
SPA is one of the major virulence factors which is present abundantly on the cell surface and 
expressed by the majority of S. aureus strains. It is also one of the most complex 
components of S. aureus. It exhibits multiple interactions against host immune machinery 
contributing towards immune evasion and pathogenesis. SPA has multiple domains. The N-
terminal region consists of a signal peptide with five repeated domains (E, D, A, B, C) which 
interacts with IgG and promotes resistance towards phagocytosis (129). The carboxyl 
terminal contains a variable region of 24bp repeat sequence called Xr region, which is widely 
used in epidemiological typing of S. aureus strains (130). SPA is found to directly interact 
with TNFR1 and EGFR via its IgG binding domains studied extensively in epithelial cells and 
macrophages (131). SPA engagement at TNFR1 and EGFR leads to increased levels of 
TNFR1 at the cell surface causing subsequent shedding of a soluble form of TNFR1 due to 
the action of ADAM17 (Figure 8) (132). Apart from that TNFR1 and SPA interaction induces 
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a pro-inflammatory signaling response by induction of IL8 release in airway epithelial cells 
via MAP kinase and NF-κB pathway (Figure 8) (131, 132). Activation of a cascade of 
signaling pathway by SPA facilitates invasion of S. aureus across epithelial barriers by 
causing cleavage of tight junction proteins such as occludin and E-cadherin (133). 
 
Figure 6: Overview of S. aureus toxins action on host immune cells. Adapted and modified from 
(134). 
1.3 THE AGR SYSTEM 
The agr operon is around 3.5kb in size and consists of two transcriptional units RNAII and 
RNAIII, which expression is controlled by the P2 and P3 promoters respectively (135). The 
RNAII encodes for four domains, AgrB, AgrD, AgrC and AgrA (135), where the AgrD 
encodes for peptide precursor which is processed to form a 7-9 amino acids long 
pheromone with a thiolactone ring structure called the auto inducing peptide (AIP) (136). 
AgrB is a transmembrane endopeptidase responsible for processing pro peptide (AgrD) into 
its functionally active final octapeptide form (137). The AgrC and AgrA act as the bacterial 
two-component signal transduction system with AgrC being a receptor histidine kinase which 
gets phosphorylated upon binding of AIP and AgrA acting as a response regulator (Figure 7) 
(138, 139). AIPs are produced during the exponential growth phase of the bacteria and upon 
reaching a threshold cell density, the agr locus gets autoactivated (135). Upon activation by 
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AgrC-mediated phosphorylation, AgrA binds to the P2 and P3 promoters of RNAII and 
RNAIII respectively (140). AgrA can also directly bind to the promoters regulating the 
expression of PSM α and β peptides (Figure 7) (115). Four classes of S. aureus AIPs, 
known as (AGR I, II, III, and IV) are present, which differ from each other based on the 
variations in the amino acid sequence (138). This diversity among the AIPs causes inter 
strain cross-inhibition i.e. peptide of one class activates the agr operon of its homologous 
group and in turn suppresses the heterologous groups (137, 138). Specific agr classes are 
also associated with specific S. aureus genetic background and several studies have 
reported a strong link between the agr class and particular clonal complexes (141). For 
example clonal lineages CC8, CC22, CC45 and CC395 usually harbor agr-I, while CC5, 
CC12, and CC15 isolates are characterized by agr-II, CC30 isolates often carry agr-III, and 
CC121 harbor agr-IV (142). The limited literature suggests a possible link between different 
agr classes and certain staphylococcal syndromes (143) with strains belonging to agr type IV 
are more commonly linked with exfoliative syndromes while strains belonging to agr-I and II 
are usually overrepresented with cases of endocarditis (143). 
Agr-mediated up-regulation of virulence factors plays a crucial role in S. aureus infection 
properties and determines the disease progression (137, 141). Inversely down-regulation of 
PSMs and up-regulation of cell surface components have been implicated in bacterial biofilm 
formation and colonization phenotype of S. aureus (137, 141). Any mutation in Agr causing 
dysfunction of Agr system is correlated with a persistent phenotype, especially identified in 
S. aureus bacteremia (144). In general, Agr-dependent up-regulation of virulence factors, 
proteases, degenerative exoenzymes and down-regulation of cell surface components 
reflect the sequential requirements for establishing specific virulence properties during 
bacterial infection. The major toxins that are under the regulation of Agr include α-toxin, a 
family of bi-component leukocidins, peptide toxins PSMs, many secreted proteases and cell 
surface protein SPA (137).  
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Figure 7: Agr control of quorum-sensing and virulence regulation in S. aureus. Modified and adapted 
from (137, 145). 
1.4 HOST-PATHOGEN INTERACTIONS 
Interactions between S. aureus and the host immune system and the nature of the host 
immune response evoked are key factors in determining the outcome during the infection. 
The major function of the immune system is to recognize and protect the host from various 
infectious agents and foreign substances. The primary defense machinery is called the 
innate immune system and it represents the first line of defense and consists of several 
branches (146). The major effector mechanisms include (i) epithelial barrier, (ii) antimicrobial 
peptide production, (iii) complement system and (iii) phagocytosis. The initial recognition and 
response is triggered by epithelial cell signaling to recruit immune cells like macrophages, 
dendritic cells, monocytes, neutrophils, and T-cells. During the initial hours innate immune 
cells like macrophages and neutrophils responds by directly killing through phagocytosis. 
Initiation of production of proinflammatory mediators like antimicrobial components, 
cytokines, and chemokines, further helps in recruiting immune cells for more efficient 
response and aid in the elimination of the pathogen. The recognition of pathogen-associated 
molecular patterns (PAMPs) by TLRs and NLRs are considered essential for the first crucial 
step of innate immune response (147, 148). Furthermore, the innate immune system guides 
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the development of pathogen-specific adaptive immune response by presenting processed 
antigens to T cells (149). These harmonized actions between innate and adaptive arms of 
the immune system are fundamental for eliminating the pathogen. 
S. aureus is a potent human pathogen by virtue of its many immune evasion strategies 
including avoiding of TLR recognition (150, 151). S. aureus expresses surface- associated 
adhesins which confer the ability to adhere cells and tissues, helps in escaping phagocytosis 
and provides resistance against host defense peptides (152, 153). Secreted proteins like 
SPA and second immunoglobulin-binding protein (Sbi) prevent IgG mediated opsonization 
(68, 131, 154). S. aureus produces complement evasion proteins like staphylococcal 
complement inhibitor (SCIN) and chemotaxis inhibitory protein of staphylococci (CHIPS). 
SCIN aids in protection against phagocytosis and neutrophil-mediated killing (155) while 
CHIPS inhibit neutrophil and monocyte migration (156). Finally, exotoxins such as cytotoxins 
cause cell and tissue damage; activate inflammasome mediators and induce excessive 
proinflammatory mediator production that impedes the efficient clearing of S. aureus. 
1.4.1 S. aureus and Airway Epithelial Response 
Polarized epithelial cells play a crucial role in mucosal defenses by sensing the pathogen 
that gains access to the airway and in response stimulating a cascade of downstream 
signaling pathway. The airway epithelial cells regulate the interface between “self” and the 
environment exposure of “non-self” antigens especially pathogens. Epithelial barrier induces 
the production of several cytokines, which plays an important role in antibacterial response. 
It also regulates the efficient recruitment and activation of neutrophils and interaction 
between the epithelium and local immune cells shapes the host response to S. aureus (157).  
1.4.1.1 TLR signaling 
The airway epithelium expresses a complete array of Toll-like receptors (TLR). Cell surface 
components of S. aureus is the primary factor recognized by the epithelial cell surface 
exposed pattern recognition receptors (PRR). Lipoteichoic acid (LTA) in the cell wall of S. 
aureus is recognized by the TLR2, which causes significant inflammation and neutrophils 
recruitment as response to epithelial infection (158, 159). Similarly a pore-forming bi 
component toxin such as PVL is also recognized by TLR2 by the epithelial cells resulting in 
NFκB signaling (Figure 8) (160). S. aureus and TLR interaction induce the production of 
several cytokines such as IL-8, GM-CSF, TNF and TGF-α and β, and it also induces the 
secretion of antimicrobial peptides by the epithelial cells (132, 161, 162). These cytokines 
plays a crucial role in recruiting and maintaining the survival of neutrophils in the airway 
(162).  
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1.4.1.2 The Inflammasome 
Inflammasomes are large cytosolic multiprotein complexes that control the activation of 
proteolytic enzymes caspases. Assembly of these complexes is dependent upon cytosolic 
sensing of pathogen-associated molecular patterns (PAMPs) such as cell surface 
molecules, toxins, and other harmful agents by the host PRRs during infection (163).  
Activation of caspase-1 downstream regulates the maturation of pro IL1β and IL18 onto 
active form as well as induction of pyroptosis (164). Several of the S. aureus exotoxins like 
α-toxin; bi component leucocidins etc. activate the NLRP3 inflammasome via TLR and pore-
formation. Inflammasome activation downstream signals Caspase-1 mediated activation of 
proinflammatory IL1 family cytokines such as IL1β and IL18, which in turn induces cell death 
via pyroptosis (134, 165). S. aureus peptidoglycan and LTA produce the primary stimulus 
followed by pore-forming toxins (α, β, γ-toxins and PVL) providing with the secondary 
stimulus for inflammasome activation (102, 166-168). IL1β also regulates the production of 
IL17 by γδ T cells and blocking the IL1 signaling reduces toxin-induced tissue pathology 
(169). 
1.4.1.3 Type I IFN signaling 
Type I IFN activation is commonly associated with S. aureus lung infection (134, 170). S. 
aureus PAMPs gaining access to the endosomal or cytosolic compartments induces type I 
IFN responses in turn resulting in the induction of STAT1, 2 and 3 transcription factors 
(Figure 8)  (134, 171).  Type I IFN influences the cell functions of a variety of cell types in the 
lung as well as induces anti-microbial responses of these cell types (171). The ability of 
different S. aureus strains to cause lung tissue damage has been linked to their ability to 
activate IFNβ signaling (172). 
 
Figure 8: S. aureus virulence factors and lung epithelial function and signaling (134, 173) 
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1.4.2 S. aureus and Skin 
Skin acts as a most important barrier that protects the body from pathogens. It is divided into 
three basic layers: the corneal, epidermis and dermis. The corneal layer acts as a major 
physical barrier, consisting of terminally differentiated keratinocytes (174, 175). While the 
epidermis is continuously reformed due to the migration of keratinocytes passively to the 
corneal layer, the dermis is composed of collagen and elastin fibers (174, 175). Apart from 
being a physical barrier skin also acts as a major immunological barrier especially against 
pathogens. PAMPs from the microorganisms are recognized by the TLRs and NLRs 
expressed on the surface of the keratinocytes (174, 176). This recognition induces the 
production of inflammatory mediators like cytokines, chemokines and antimicrobial peptides 
against the invading pathogens. This cutaneous immune response also triggers recruitment 
of immune cells like neutrophils as well as activates resident immune cells like Langerhans 
cells, macrophages, NK cells, plasma cells, T and B cells, which together can coordinate an 
efficient cutaneous immune response to clear the pathogens (174-176). 
1.4.2.1 Response during skin colonization 
The surface of the skin has developed certain attributes to prevent the colonization of S. 
aureus, such as low temperature and low pH. The skin effects the expression of bacterial 
cell surface factors such as ClfA, CLfB and FnbpA and thereby reducing the growth of S. 
aureus (177, 178). Keratinocytes constitutively express antimicrobial peptides which directly 
affect the bacterial growth (bacteriostatic or bactericidal) as well as regulate the resident 
immune cell response against S. aureus infection (179, 180). However, S. aureus colonizing 
in the skin is found to produce aureolysin a metalloproteinase which inhibits the antimicrobial 
peptides activity (181). At the same time, S. aureus has evolved to colonize the skin by 
expressing a wide array of microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) proteins on its cell surface to promote binding and adherence 
(182, 183).The superantigens produced by S. aureus skew the T cell immune response 
more towards Th2 phenotype and thus contributing towards enhanced skin colonization 
(184).  
1.4.2.2 Response during skin infection 
The PRRs on the surface of the keratinocytes recognize the S. aureus cell surface factors 
such as LTA, peptidoglycan etc. and activates the production of proinflammatory molecules 
such as cytokines, chemokines and tissue-resident immune cells (185, 186). Pore-forming 
toxins of S. aureus such as α-toxin, bicomponent leucocidins such as PVL, LukED etc. 
causes keratinocyte lysis and activates inflammasome signaling. Activation of caspase-1 by 
inflammasome is crucial for cleavage of pro- IL1β onto its active form (187). IL1β mediated 
neutrophil recruitment is required for S. aureus clearance and plays a crucial role against 
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deep-seated S. aureus skin infections like cellulitis and folliculitis (188, 189). Both IL1α and 
IL1β contribute equally against superficial skin infection such as impetigo (188). In addition 
secretion of IL17 by T cell subsets such as Th17 cells, NKT cells, and γδ T cells also plays a 
critical role in neutrophil recruitment as a host defense against cutaneous S. aureus 
infections (190, 191). 
1.4.3 S. aureus and Neutrophils 
Neutrophils are critical components of the first line of host defense against infectious agents 
as they are capable of producing non-specific antimicrobial effector responses. The majority 
of healthy individuals are usually protected against severe S. aureus infections, largely due 
to the protective role played by neutrophils in host immune responses. To facilitate rapid 
recruitment to the site of infection large numbers of neutrophils are maintained in the 
circulation. Circulating neutrophils are recruited to the site of infection mainly by host-derived 
chemotactic factors, among others IL-8, GCP-2, complement factor C5a, HMGB1 etc. (192-
194). The whole process of neutrophil recruitment to the tissue site is broadly divided into 
four steps including rolling adhesion, integrin activation, firm adhesion and transmigration. 
Initially, neutrophils adhere to the blood vessel by repetitive ligand-receptor binding (192, 
193). Further, neutrophil-endothelial cell interaction takes place by the activation of 
lymphocyte function associated antigen-1 (LFA-1); followed by LFA-1 binding onto 
intracellular adhesion molecules (ICAM-1 and ICAM-2) on endothelial cells causing 
neutrophil capture (192, 193, 195). This induces cytoskeletal rearrangements initiating 
morphological changes from spherical to flat in neutrophils, causing transmigration from the 
endothelium into infected tissue (195). The primary role of neutrophils in the host-defense 
mechanism is phagocytosis of pathogens recognized by the PRRs (196, 197). This process 
is usually enhanced when the microbes are opsonized and recognized by IgG and 
complement receptors on neutrophils (198, 199). Upon phagocytosis NADPH oxidase 
complex generates high levels of reactive oxygen species (ROS); this superoxide anion is 
readily converted into hydrogen peroxide, other secondary oxygen derivative, and 
hypochlorous acid which contribute towards microbicidal activity (200, 201). Apart from this 
neutrophils also produces several degradative enzymes and cationic peptides like 
cathepsins, elastase, defensins, proteinases etc. contained in its granules which facilitate the 
efficient killing of bacterial pathogens (202, 203). 
1.4.3.1 S. aureus neutrophil evasion 
S. aureus is capable of overcoming neutrophil-mediated killing by producing several 
secreted and surface bound factors that alter the functional capacity of neutrophils. The 
chemotaxis of both neutrophils and monocytes are inhibited by CHIPS through directly 
binding to the C5a and FPR, and also thereby inhibiting phagocytosis (156, 204). 
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Complement-mediated opsonization of S. aureus is inhibited by SCIN, extracellular 
fibrinogen-binding protein (Efb) and extracellular complement-binding protein (Ecb). Similarly 
SPA and Sbi interacts with the Fc region of the immunoglobulins to inhibit phagocytosis 
(155, 205, 206). To protect and counter the cytotoxic effect of ROS and antimicrobial 
peptides inside the phagosome S. aureus is known to produce superoxide dismutases, 
catalase, hydroperoxide reductase and staphyloxanthin (207-209). Furthermore, S. aureus 
secretes several of the cytotoxins including PSMs, PVL, and LukAB which specifically target 
neutrophils by causing pore formation and inducing osmotic lysis (90, 106, 112, 113, 118).  
 
Figure 9: S. aureus neutrophil evasion mechanism (197, 210) 
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2 AIMS 
This project focuses on severe invasive infections caused by S. aureus. The incidences of 
these infections are rising, and unusually severe pathological signs are associated with 
certain Community Acquired (CA) S. aureus types with superior transmissibility and 
virulence. Here we seek to obtain insight into CA S. aureus infections, including molecular 
characterization of strains in the community, mechanistic studies to identify mechanisms 
contributing to lethal necrotizing S. aureus infections, as well as understand the role of 
specific staphylococcal toxins and virulence regulation in the pathologic events leading to 
the destructive infections in lung and skin. 
 
Specific aims are: 
 To establish the antibiotic resistance profile, genetic lineage and to determine 
toxins and virulence traits of S. aureus strains isolated from both colonizers and 
patients with invasive infection. 
 
 To determine how diversity in exotoxin profiles among CA S. aureus strains 
translates into virulence-associated functional responses. 
 
 To delineate the role of specific staphylococcal exotoxins in mediating tissue injury 
and to define correlates of severe lung pathology associated with pneumonia. 
 
 To identify the underlying mechanism of the genetically related clinical ST22 MRSA 
strains displaying starkly different phenotypic response profile and to explore how 
this influences infection outcome. 
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3 METHODOLOGY 
A detailed description of the experimental procedures used in this thesis is found in the 
respective articles and manuscripts. In this section, a brief summary and overview of some 
of the experiments are presented here. 
 
Bacterial strains 
A total of 68 S. aureus isolates were included in paper I, of which 38 were from healthy 
nasal carriers and 30 from various infection sites. S. aureus isolates were selected based on 
the growth in chromogenic agar and further characterized using various biochemical and 
molecular confirmatory experiments. In paper II, 38 strains from the above heterogeneous 
cohort of CA S. aureus strains were selected randomly to represent different ST types and 
toxin profiles from both colonized as well as from patients with varying infections. Similarly, 
this study also included a confirmatory homogenous cohort of 31 isolates collected from 
patients with CA S. aureus pneumonia. In the next study in paper III, we focused specifically 
on lung infections of varying severity. Clinical S. aureus isolates collected from pleural fluid 
of patients with varying severity of pneumonia, including two cases of necrotizing pneumonia 
(NP753 and NP796) and one milder case of lung empyema (LE2332) were selected from 
the characterized strain collection in paper I. The results obtained from these strains were 
then confirmed using a larger cohort of strains causing pneumonia. In paper IV we 
specifically focused on ST22 MRSA isolates causing skin infection. This thesis overall 
focuses on well-characterized clinical S. aureus strains causing various infections. An 
advantage of using clinical strains in contrast to certain lab strains is due to the fact that 
virulence properties are well preserved as well as ensures results of high clinical relevance. 
 
Proliferation assay 
This assay is commonly used to functionally asses the superantigen-mediated proliferation 
of immune cells, i.e. T-cells. The superantigen-mediated proliferative responses will be 
influenced by the presence of cytotoxins eliciting cytotoxicity and targeting specific immune 
cells. Phytohemagglutinin-L (PHA) was used as a positive control for polyclonal T cell 
activation and expansion. 
 
Organotypic tissue models 
We speculate that tissue-specific pathogen-elicited host responses may explain tissue 
tropism and disease manifestations of acute severe bacterial infections. Thus, it is likely that 
pathogen-specific toxins and host derived inflammatory mediators at the local site of 
infection both contribute significantly to disease progression and outcome. In this context, 
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human tissue models can capture important aspects of host associated responses to 
infections, since many important human pathogens (e.g. group A streptococcus and S. 
aureus) induce species-specific responses. To approach this we have used an innovative 
human 3D organotypic human lung/skin tissue model system in combination with bacterial 
stimulation assays as means to predict virulence and pathogen-elicited tissue responses.  
 
Figure 10: A) Schematic drawing depicting setting up of organotypic tissue models. Representative 
hematoxylin/eosin staining image of (B) Lung tissue model, and (C) Skin tissue model. Modified and 
adapted from (211, 212). 
To investigate the impact of S. aureus on human tissue-specific cells, we used a human 3D 
organotypic lung/skin tissue model in which cells retain their differentiated cellular 
phenotypes in an in vivo like architecture; thus allowing for experiments under more 
physiologic conditions. Epithelial cells are stratified on a layer of fibroblasts as shown in 
(Figure 10). In our model, epithelial and fibroblast cell lines are used as they allow for 
reproducibility as compared to using genetically non-uniform and potentially impure primary 
cells. In these tissue models, stromal cells acquire a polarized phenotype and a large 
number of cell-cell contacts between stromal cells occur. Also, production and deposition of 
important tissue components are seen. Thus, the model is well suited for studies on tissue-
specific responses to bacterial provocation in a physiological relevant setting. These 
systems, therefore, provide unique models in which mechanisms of disease manifestations 
and the events directing acute severe infections can be monitored in real-time. 
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Confocal microscopy and live imaging 
Microscopy based methods have been very useful and a widely used technique during the 
course of this thesis projects. Confocal microscopy was used to characterize and quantify 
the structural and cellular proteins in the tissue models stimulated with bacterial toxins or live 
infection. It was also used to visualize and determine the localization/association of S. 
aureus with host cellular compartments during infection. 
Live imaging method was employed mainly due to the fact that this technique enables 
studies on visualization and quantification of tissue integrity determination, cellular process 
and localization of molecules in real time within the live tissue. Lung tissue models were 
constructed using GFP expressing epithelial cells and were stimulated with bacterial 
supernatants or pure toxins.  Live imaging experiments was performed over a time period of 
16 hours at 20 min intervals between each image and were captured by acquiring 3D z-
stacks at 3 µm z-dimension resolution, the volume of 512 x 512 µm in x and y-direction and 
120-150 µm in the z direction. Finally, tissue integrity was determined by quantifying the total 
intensity sum of GFP expression over the period of time after stimulation. Due to the more 
transparent nature of the tissue models as compared to the real tissues, deep penetration of 
the laser into the models was possible, with a reduced scattering of the light. 
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4 RESULTS AND DISCUSSION 
4.1 MOLECULAR CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS STRAINS 
FROM THE COMMUNITY  
S. aureus is a significant cause of human infections and an emerging health problem 
globally. The prevalence of S. aureus infections varies worldwide among countries. The 
increasing use of antibiotics has resulted in multi-drug resistant S. aureus due to selective 
pressure. Consequently, the emergence of MRSA infections is a major cause of concern in 
most countries, with high antibiotic resistance including Vancomycin resistance which in 
some cases has left physicians with limited options for treatment (7, 213). In India, antibiotics 
consumption is rampant and the rate of MRSA in clinical samples, as well as carriage in the 
community, is high (30-70%) (214). The advent of CA-MRSA into the hospitals replacing the 
HA-MRSA strains in the past decade has resulted in increased drug resistance, mainly in 
countries where the prevalence is high (215). Studies on Indian CA-MRSA especially their 
molecular characteristics and clonal complexes present have not been studied in detail. 
Therefore, in the first study of this thesis we characterized Indian CA-MRSA and MSSA 
strains from rural and urban healthy carriers and disease isolates from pus, blood etc. from 
patients visiting hospitals. The aim was to study the distribution of SCCmec elements, 
sequence types (STs) and their toxins and virulence factors profile in the community and 
hospital environment. Carriers were chosen to include only those with no identified risk 
factors for MRSA acquisition including, prior hospitalization, use of antibiotics and surgeries 
in the past year. Carrier isolates (n=38) were obtained from nasopharynx swabs.  Disease 
isolates (n=30) were recovered from wounds, pleural fluid and blood cultures in hospitals 
from 4 different cities within India. The isolates were characterized using MLST, spa typing, 
PFGE, SCCmec typing, agr typing, virulence gene content and antibiogram (CLSI 2005). 
Molecular characterization was complemented by virulence gene microarray of selected 
isolates, the analysis is presented in Table 1 (Paper-I). 
4.1.1 Antibiotic Resistance 
Among the isolates, the overall MRSA rate was 41% with 26% of carrier isolates and 69% of 
disease isolates containing mecA gene. Antibiotic sensitivity to five antibiotics was tested 
and the following resistance percentages were observed: oxacillin (n =16; 24%), cefoxitin (n 
=18; 27%), erythromycin (n =12; 18%), gentamycin (n =20; 29%) and tetracycline (n = 0). 
The antibiotic sensitivity pattern among carrier and disease MRSA isolates were similar to 
each other (Figure 11). A major difference in antibiotic sensitivity pattern was identified 
between carrier and disease MSSA isolates where the majority of the carrier MSSA isolates 
(76%) were sensitive to all antibiotics tested in contrast to only 33% of the disease MSSA 
isolates being sensitive to all antibiotics. Among disease, MSSA isolates 25% of them had 
resistance determinants for gentamicin and/or erythromycin (Figure 11). This is in 
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accordance with a follow-up study on a larger cohort showing MSSA strains exhibiting 
increased resistance towards certain antibiotics (216). Similarly, few isolates were neither 
completely sensitive nor resistant to the antibiotics tested in terms of their MIC values; such 
strains were categorized as intermediate resistant strains.   
 
4.1.2 Major MLST types and their virulence gene profile 
In paper I, even from a small number of strains collections of 68 isolates, 15 different STs 
including isolates resembling S. aureus from animal origin were identified. MSSA isolates 
were more diverse and heterogeneous in their genetic background as compared to MRSA 
isolates. The major ST type (ST22, ST772, and ST121) represented more than 10% of the 
isolates and ST1208 and ST672 were identified as emerging clones. 
ST22 formed the dominant clone both among carriers and disease isolates making up 28% 
of the total strain collection. Sixty eight percent of the ST22 isolates were mecA positive and 
had SCCmec IV element, and a PFGE pattern resembling that of EMRSA-15 but exhibiting 
some variation (217). These strains are found to replace the traditional HA-MRSA strains in 
many countries like Germany, Portugal and Singapore (218-220). Similarly, ST239 HA-
MRSA strains with SCCmec III or IIIA that previously circulated in the hospital environment 
are being replaced by ST22 MRSA strains (221). All ST22 isolates were belonging to agr 
type I, capsular type 5 and positive for PVL and egc.  
ST772 was the second major clone with 69% of the strains being methicillin-resistant, 
belonging to SCCmec type V and agr type II. All the isolates were capsular type 5, PVL, egc 
positive, and contained combination of several enterotoxin genes. The type V SCCmec 
cassette in these strains contained the second ccrC region similar to that of SCCmec ZH47 
mosaic cassette as previously reported. The above noted low-level resistance towards 
oxacillin might be attributed towards the composite nature of the SCCmec type V cassette in 
these strains (222). This was further confirmed by whole genome sequencing studies on 
Figure 11: Antibiotic resistance pattern 
among carrier and disease MSSA and 
MRSA isolate. R: Resistant, I: Intermediate 
resistant, S: Sensitive 
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these Indian ST772 strains, identifying a novel type V (5C2) SCCmec element in many while 
the others have a composite SCCmec type V element (5C2&5) formed by the integration of 
type V SCCmec into an MSSA carrying SCC element (223). 
ST121 clones were detected in 10% of the isolates and all the strains were methicillin 
sensitive and negative for mecA gene. All ST121 strains identified in this study belong to agr 
type IV, capsular type 8, and are PVL and egc positive. 
In paper I, we have characterized Indian S. aureus isolates which belong to a wide variety of 
ST types. Even in a small collection of isolates (n=68), strains belonging to 15 different STs 
were identified, with MSSA isolates exhibiting the greatest heterogeneity. Similar diversity 
among MSSA strains has been recently reported from a study conducted in China (224). 
The most obvious bias in the study is the limited number of isolates collected, but our results 
are in part concordant with the existing literature: the two major MRSA STs (ST22 and 
ST772) being reported earlier, as well as a greater heterogeneity among MSSA, isolates as 
compared to MRSA strains (221, 224, 225). Many of the STs are being reported for the first 
time in this study. Sixty nine percent of the isolates carried PVL genes and the superantigen 
genes egc were found in 84% along with many other toxins. This high prevalence of PVL 
and egc genes among Indian MSSA and MRSA isolates is unlike the situation in other South 
Asian countries, where only MSSA strains contain PVL (226, 227). In addition, detailed 
molecular analysis of Indian S. aureus isolates along with their virulence repertoire is 
reported here for the first time which might lead to a better understanding of the 
characteristics of circulating clones in the community and the disease caused by these 
strains. 
 
4.2 COMMUNITY S. AUREUS ELICITS STABLE CYTOTOXIC OR PROLIFERATIVE 
RESPONSES IN HUMAN PBMC: LINK TO AGR TYPE AND ALPHA-TOXIN 
LEVELS 
The ability of S. aureus to cause multitude of infections is linked to the production of a wide 
array of virulence factors. Several virulence factors have been implicated in disease 
pathogenesis, including Panton-Valentine Leukocidin (PVL), alpha-toxin (α-toxin), 
superantigens and phenol soluble modulins (67, 98, 118, 228). These virulence factors are 
regulated and controlled by a global regulator system called the agr system. A recent study 
demonstrated that allelic variation on agr translates into significant differences in expression 
of several virulence factors (229). 
In paper II we wanted to assess the virulence properties and functional responses of 
community S. aureus strains with distinct toxin profiles as characterized in paper I. In 
particular, we sought to analyze the responses elicited by bacterial supernatants prepared 
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from overnight cultures of the isolates. Such supernatants contain a mixture of secreted 
virulence factors including both superantigens and cytotoxins. Based on humoral responses 
against superantigens and cytotoxins that develop in patients, it is clear that these toxins are 
expressed in vivo. Although we cannot account for potential differences in vitro and in vivo 
expression of virulence factors, we believe that the use of supernatants more closely reflects 
what the patients are exposed to as compared to purified toxins. Exactly how these different 
combinations of toxins affect virulence and host responses is not yet fully elucidated. 
A heterogeneous cohort of community S. aureus strains (n= 38), both MRSA and MSSA, 
collected from colonized individuals and patients with varying S. aureus infections were used 
in this study (paper II). This isolate collection had been characterized with respect to 
antibiotic resistance profile, molecular typing including Sequence Type (ST), Agr-types, and 
toxin profile as determined by microarray in the previous study (paper-I).  
4.2.1 Functional properties of clinical S. aureus isolates: proliferative or cytotoxic 
profiles 
Bacterial supernatants were initially tested in a proliferation assay, in which peripheral blood 
mononuclear cells (PBMC) were stimulated with different dilutions (1:50, 1:100 and 1:1000) 
of the bacterial supernatants (Figure 1A and 1B paper II). This is commonly used to 
functionally assess superantigenic responses elicited by S. aureus isolates but the response 
will be influenced by the presence of cytotoxins. The supernatants demonstrated striking 
differences in their ability to trigger proliferative responses, and they displayed robust 
response profiles, either a proliferative or cytotoxic. A proliferative profile was denoted when 
strains induced proliferative responses at all dilutions. A cytotoxic profile was assigned when 
the strains did not elicit a proliferative response in the more concentrated supernatants (1:50 
and 1:100). This was not mainly due to lack of superantigenic activity, as strong proliferative 
responses were noted in the most diluted samples; thus, indicating a cytotoxic effect rather 
than lack of superantigen-mediated proliferation. To assess this further, flow cytometry 
analysis was performed using stimulated cells stained for dead cell marker plus cell surface  
CD3, HLA-DR, and CD45. Proliferative supernatants induced expansion of T cells, while 
cytotoxic supernatants induced significant cell death (Table 1 and Figure 1E; paper II).  
Thus, demonstrating that in some strains the superantigens trigger proliferative responses, 
but this activity is masked by toxin-mediated cytotoxic responses.  The two functional profiles 
could be found in both colonizing isolates as well as from invasive cases, and there was no 
significant association between functional profile and ST-type/clonal complex or 
MRSA/MSSA (Table 1; paper II).  
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4.2.2 Significant association between agr type and proliferative or cytotoxic profile  
Expression of many secreted S. aureus virulence factors, including superantigens and 
cytotoxins, is controlled by a global regulator called the agr (accessory gene regulator) 
system. The agr is an autoinducing, quorum-sensing two-component system for which four 
different allelic variants were identified (agr I-IV). Comparison of functional profile to agr type 
revealed a significant correlation with agr II and agr III strains predominantly showing a 
proliferative profile whereas agr I and IV strains were cytotoxic (Figure 1F; paper II). As this 
analysis was conducted on a highly heterogeneous strain collection, including both 
colonizing and invasive CA S. aureus strains from India, we wanted to also test a more 
homogenous isolate collection.  To this end, we tested isolates collected from patients with 
CA S. aureus pneumonia in France. Also in this isolate collection, a similar association with 
agr I and agr IV being significantly more cytotoxic than agr II or III was noted (Figure 1G; 
paper II). By virtue of agr being a global regulator of virulence factors including both 
cytotoxins and superantigens, it seems likely that the noted association is linked to varying 
toxin production.   
4.2.3 α-toxin expression correlates with cytotoxicity against PBMC 
Next, we sought to delineate the factors responsible for the cytotoxic response profile. S. 
aureus express a wide array of virulence factors, which contribute in various ways to disease 
pathogenesis. Among several putative determinants of community S. aureus virulence, the 
cytotoxins α-toxin and PVL have been implicated in severe invasive infections. To assess 
their potential contribution to the functional profile, the amounts of α-toxin and PVL were 
determined in all bacterial supernatants. The results demonstrated a striking correlation 
between the amount of α-toxin and cytotoxic response; the cytotoxic supernatants had 
significantly higher levels of α-toxin than did the proliferative, regardless of whether the 
strains were collected from the patients, colonized or CA pneumonia cohort (Figure 2A; 
paper II). In contrast, there was no significant correlation between the proliferative or 
cytotoxic profile of strains and PVL expression (Figure 2B; paper II). Thus, the data strongly 
implied that α-toxin contributed to the noted cell death in PBMCs. This was further confirmed 
by stimulating PBMC with PHA and pure α-toxin, which revealed a clear dose response 
where higher amounts of α-toxin resulted in higher cytotoxicity (Figure 3A; paper II) as well 
as stimulation experiments using isogenic α-toxin and PVL mutants (Figure 3C and 3D; 
paper II). Of note, the majority of the cytotoxic supernatants contained ≥ 225 ng/ml α-toxin, 
whereas proliferative supernatants always had low levels of α-toxin productions i.e. < 
221ng/ml. Thus, it is tempting to speculate that there exists a critical threshold of α-toxin 
concentration that determines the cytotoxic response and underlines the importance of 
quantifying the toxin levels rather than the traditional epidemiological method of just 
determining their presence at the genetic level. The amount of toxins secreted by the 
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individual strains seems to influence their virulence property and may play a crucial role in 
disease outcome. Furthermore, in accordance with the above results significantly, higher 
levels of α-toxin were found in strains belonging to cytotoxic agr type I and IV as compared 
to the proliferative agr type II and III (Figure 2C; paper II). A study assessing variation in 
kinetics and degree of agr signaling showed that strains belonging to agr type I and IV had 
the earliest and strongest agr signaling induction as compared to agr type II and III strains 
(229). The molecular basis for this hierarchy in signaling strength and link between agr type 
and response profile due to varying levels of secreted AIPs is not yet fully elucidated. 
Furthermore, the clinical relevance of these distinct functional profiles remains to be shown.  
In conclusion, the study in paper II, reveals robust functional response profiles, either 
proliferative or cytotoxic, in community S. aureus isolates. The response profiles were 
associated with agr type and low or high α-toxin production, and it seems likely that distinct 
functional response profiles could influence the clinical manifestation and that it might reflect 
specific pathotypes. To explore such a linkage would require large epidemiologic materials 
consisting of strains from different genetic lineages and, agr types combined with well-
defined clinical data. Similarly, whether the differential phenotypic response profiles elicited 
by S. aureus strains can be utilized as a diagnostic or as an epidemiological surveillance tool 
to differentiate between strains capable of causing cytotoxic response versus strains eliciting 
a superantigen-mediated systemic response in patients can at present only be speculated 
upon. 
 
4.3 TOXIN-MEDIATED PATHOLOGY IN A HUMANIZED LUNG TISSUE MODEL 
EXPOSED TO S. AUREUS TOXINS 
Necrotizing pneumonia is one of the most severe manifestations of invasive CA S. aureus 
infections. PVL-positive strains and CA S. aureus have been epidemiologically linked to 
these life-threatening infections (49, 98). However, studies of pathogenesis have implicated 
different toxins, including PVL, α-toxin and phenol-soluble modulins (67, 98, 118). These 
contradicting results have partly been attributed to use of animal models significantly less 
sensitive to the toxins as compared to humans (99). Although necrotizing pneumonia is 
recognized as a toxin-mediated disease, the mechanisms underlying the clinically important 
tissue destruction remains unclear. Progress in the field has been hampered by the lack of 
experimental models that allows for studies of toxin-mediated effects in human lung tissue. 
This underscores the importance of using clinically relevant susceptible host for the study of 
toxin-mediated pathology. 
In paper III, we focused on the pathogenesis of CA S. aureus necrotizing pneumonia, in 
particular elucidation of the tissue destructive events. To investigate the impact of specific S. 
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aureus exotoxins on human tissue-specific cells, we used a human 3D organotypic lung 
tissue model. Our working hypothesis is that several different toxins will contribute to tissue 
pathology, but they may target different cells and their impact may be tissue-specific. 
4.3.1 Necrotizing pneumonia isolates mediated strong cytotoxicity and increased 
tissue disruption 
To study toxin-mediated tissue pathology, contributing to S. aureus pneumonia three CA-
MSSA S. aureus strains isolated from patients with a lung focus of infection, including two 
severe cases of necrotizing pneumonia (strains NP796 and NP753) and one milder with lung 
empyema (strain LE2332), were selected from the strain collection described in paper I. 
These strains were characterized with respect to molecular types and virulence profiling 
using microarray analyses (paper I and paper III Table S1). The two necrotizing pneumonia 
isolates were both ST121 type, agr type IV and shared an identical exotoxin gene profile, 
whereas the lung empyema strain was an ST30 type and agr type III (paper III; Table 1). As 
a reference strain, the epidemic CA-MRSA USA300 strains 11358 and LUG2012 was used. 
Initially, we tested the bacterial supernatants from overnight cultures of these strains in a 
proliferation assay as explained in paper II. The supernatants elicited starkly different 
responses i.e. both necrotizing pneumonia strains displayed cytotoxic response profiles 
whereas the lung empyema strain a proliferative response profile (Figure 12A). Cytotoxicity 
was further confirmed by adding bacterial supernatants together with the PHA, which resulted 
in a reduction of PHA-response in the presence of the necrotizing pneumonia supernatants, 
but not the lung empyema supernatant (Figure 12B). Flow cytometry analysis in PBMC 
cultures exposed to supernatants from the necrotizing pneumonia strains showed that 97% of 
the cells were positive for dead cell marker (Figure 12C).   
Figure 12: Representative proliferative or cytotoxic responses by human PBMCs stimulated with 
indicated dilution of bacterial supernatants. A) Stimulation with bacterial supernatants alone. B) 
Stimulation with the addition of PHA. C) Representative histogram of flow cytometry data as defined by 
dead cell marker positivity among PBMC stimulated with LE2332 (green), NP753 (red full), NP796 (red 
dashed), USA300 (11358) (blue), unstimulated (black). 
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Also, other relevant cell types such as human primary neutrophils and lung epithelial cells 
were exposed to the supernatants. The necrotizing pneumonia isolates were highly cytotoxic 
to both lung epithelial cells and neutrophils whereas the lung empyema isolate lacked 
cytotoxic activity towards lung epithelial cells and was moderately cytotoxic towards 
neutrophils (Figure 1A and 1B; paper III). This corresponded to higher levels of PVL and α-
toxin being produced by the two necrotizing pneumonia isolates, as compared to the lung 
empyema isolate that produced low levels of PVL but no α-toxin (Table1; paper III). Taken 
together, the data revealed cell-specific responses, demonstrated by α-toxin targeting PBMC 
(paper II) and lung epithelial cells but not neutrophils (paper III), whereas PVL only targeting 
neutrophils. Using the lung tissue model, histological analysis of sections of the tissue model 
revealed that in unstimulated models, the epithelial cells remained intact on top of the 
fibroblast matrix layer while tissue injury including breakage of the epithelial mucosa barrier 
as well as dissociation of epithelial cells from the fibroblast matrix layer was accentuated in 
lung tissue models exposed to necrotizing pneumonia isolates as compared to the lung 
empyema isolate (Figure 1C and 1D; paper III). Exposure of lung tissue models to toxins 
secreted by strains causing necrotizing pneumonia (NP753, NP796) vs lung empyema 
(LE2332) exhibited varying response and the epithelial damage elicited by these strains 
correlated with the observed clinical severity.  
4.3.2 α-toxin and PVL mediated cell-specific cytotoxicity contributes towards 
epithelial damage 
In paper II, we report that α-toxin contributes to cytotoxicity against PBMC, and it is well 
recognized that the main target of PVL is neutrophils. We, therefore, quantified the levels of 
α-toxin and PVL in the bacterial supernatants and the results showed that the two necrotizing 
pneumonia isolates produced high levels of both PVL and α-toxin, whereas the lung 
empyema isolate produced moderate levels of PVL but low levels of α-toxin (Table1; paper 
III). This furthermore suggests that α-toxin might be a key factor mediating epithelial damage. 
To test this assumption and to determine the kinetics of cytotoxic events, live imaging 
experiments of lung tissue models exposed to supernatants or pure toxin was performed. 
Epithelial disruption was evident within 2 to 3 hours and maximum cytotoxicity was attained 
by 6 hours in NP753 supernatant and pure α-toxin stimulated lung tissue models (Figure 2C 
and 2D; paper III). Further experiments from toxin-deficient mutants verified that α-toxin was 
the major mediator of epithelial disruption which is in line with previous findings (230, 231). 
A recent study identified ADAM10, a metalloprotease, as a receptor for α-toxin (71). In line 
with this finding, we found that lung epithelial cells expressed high levels of ADAM10; 
PBMCs expressed intermediate levels whereas neutrophils expressed low levels of 
ADAM10. Thus, the noted cell-specificity in α-toxin mediated cytotoxicity was coupled to a 
differential receptor expression. Previous studies have described that interaction between α-
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toxin and ADAM10 may result in an activation of the protease activity of ADAM10 and 
consequently lead to cleavage of the tight junction protein E-cadherin (72). We found a 
distinct loss of E-cadherin in lung model stimulated with necrotizing pneumonia strain as 
compared to the lung empyema strain (Figure 2H and 2I; paper III). This further supports 
that α-toxin has a key role in tissue damage, not only through its direct cytolytic activity but 
also through its interaction with the metalloprotease ADAM10 resulting in loss of important 
adherence junction proteins such as E-cadherin.   
To include also neutrophils in this setting and to decipher contribution of PVL-mediated 
neutrophil lysis on epithelial damage, culture supernatants from neutrophils stimulated with 
the bacterial supernatants were added to the lung models, alone or in combination with 
bacterial supernatants/pure α-toxin (Figure 3A-C; paper III). The results revealed that 
addition of stimulated neutrophil supernatants further augmented the tissue pathology. In 
lung models, addition of neutrophil supernatant stimulated with lung empyema strain 
enhanced the level of tissue destruction to the same degree as in models stimulated with 
necrotizing pneumonia strains (Figure 3A; paper III). The data thus showed that PVL 
contributed to epithelial damage indirectly by triggering neutrophil lysis. Neutrophil-released 
contents like granule proteases and other factors have previously been shown to cause 
epithelial damage (100, 232). Taken together, this implies that both α-toxin and PVL will 
impact tissue destruction by targeting different cells and that most severe tissue damage is 
elicited by a combined action of α-toxin and PVL.  
We also analyzed bacterial supernatants containing known amounts of α-toxin and PVL in a 
larger collection of CA-pneumonia strains (Table S2; paper III). The results revealed that α-
toxin levels correlated with cytotoxicity against lung epithelial cells (Spearman r=0.68; 
p=<0.0001) but not with neutrophils. In contrast PVL levels correlated with cytotoxic response 
towards neutrophils (Spearman r=0.56; p=0.001) but not with lung epithelial cells. Similar 
results were obtained also in lung tissue model experiments where α-toxin levels correlated 
with direct epithelial damage while high levels of PVL correlated with neutrophil-mediated 
epithelial damage (Figure 5B and 5C; paper III). Notably dividing the strains according to 
their clinical outcome demonstrated that strains expressing high levels of α-toxin and PVL 
were largely found in the non-survivor cohort and that higher cytotoxicity towards both 
epithelial cells and neutrophils was more prevalent among strains associated with fatal 
outcome as compared to survivors. These data on clinical isolates is concordant with our 
previous observation of a combined role for both high α-toxin and PVL levels in severe 
disease manifestations. These data underlines the importance of quantifying the levels of 
toxins rather than solely measuring their presence at gene level as well as determining the 
cytotoxic activity of these strains in relevant cell types in clinical and epidemiological studies.  
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4.3.3 Augmented inflammation, tissue necrosis and chemotactic responses 
induced by S. aureus toxins in lung tissue model.  
Furthermore to characterize the level of tissue pathology caused by the bacterial 
supernatants, the tissue was analyzed for HMGB1 and CXCL8. The results revealed that 
HMGB1 and CXCL8 expression were accentuated in epithelial layer exposed to necrotizing 
pneumonia strains as compared to lung empyema (Figure 4; paper III). Thus, these 
inflammatory responses are in complete agreement with the differential tissue damage 
elicited by the strains. As necrotizing pneumonia is characterized by a massive influx of 
neutrophils to the site of infection, we explore whether stimulated epithelium influenced 
neutrophil migration. Using a transwell migration assay, conditioned media from S. aureus 
toxins exposed lung tissue models induced a strong chemotactic response and caused 
significant migration of neutrophils over a broad concentration range (Figure 4G and 4H; 
paper III). Notably, these effects were seen even at sublytic concentrations of the toxins and 
it can be noted that this induction of neutrophil migration, infiltrating the tissue environment 
can further exacerbate tissue pathology. 
In our previous studies in paper II we showed that IVIG efficiently inhibited α-toxin-mediated 
cytotoxicity and superantigen-mediated proliferation (Figure 4A and 4B; paper II). Here we 
tested whether this toxin-mediated tissue pathology can be blocked by addition of IVIG. Live 
imaging experiments revealed that epithelial damage mediated by both bacterial supernatant 
and supernatants from stimulated neutrophil was completely abrogated by IVIG (Figure 13, 
Figure 6D and 6E; paper III). In line with previous reports (233-235), our data support a 
beneficial role of IVIG in pneumonia through its broad spectrum of antibodies against toxins 
can prevent toxin-mediated tissue damage. 
 
In this study in paper III we demonstrate that severe lung tissue pathology is associated with 
a combination of high levels of both α-toxin and PVL, and fatal outcome correlated with 
higher toxin production and cytotoxic activity in pneumonia isolates. Both α-toxin and PVL 
were found to elicit strong upregulation of chemokines in the lung epithelium which resulted 
Figure 13: Live imaging analyses of GFP-
expressing lung tissue stimulated with supernatant 
from NP753 or NP753 stimulated neutrophils 
without IVIG (left panel) and with IVIG (right panel). 
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in increased neutrophil chemotaxis. This demonstrates that toxin-mediated pathology is not 
limited to cytolytic events. Taken together, the data demonstrate a dual role for the toxins 
involving both cytolytic and chemotactic responses, and underscore the importance of 
targeting multiple toxins and inflammatory pathways in the treatment of severe S. aureus 
pneumonia (Figure 14). The study in paper III mainly focused on understanding toxin-
mediated pathology under well-defined conditions using a human 3D lung tissue model, and 
which may not necessarily reflect the full course of infection as live bacterial infection may 
trigger many different pathways in terms of adaptation, spatial distribution, and interactions 
with the host. Hence, further experiment’s focusing on long-term live infections on tissue 
models made with innate immune cells can open up new avenues for detailed studies of 
host-pathogen interactions, testing of novel antibiotics treatment and intervention strategies 
in a human tissue-like setting.  
 
Figure 14: Schematic presentations of the results in paper III. 
 
4.4 PHENOTYPE SWITCH IN S. AUREUS ST22 STRAINS CAUSING SKIN 
INFECTIONS IS REGULATED BY A POINT MUTATION OF RECEPTOR HISTIDINE 
KINASE AGRC   
Staphylococcus aureus is one of the major causes of skin and soft tissue infections. 
Epidemic MRSA-15 (EMRSA-15), belonging to sequence type ST22 is one of the most 
critically expanding MRSA clone world-wide. Recent studies have identified ST22 as most 
markedly expanding MRSA clone in Europe (236). Apart from that in countries like India 
where the prevalence of MRSA is high, ST22 MRSA strains are replacing the previously 
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circulating HA-MRSA strains in a hospital environment (221). Several studies have reported 
PVL positive ST22 strains being associated with skin infections (237-239) as well as 
outbreaks of neonatal infections, which are particularly concerning (240). S. aureus 
expresses a wide array of virulence factors, including a plethora of secreted toxins and a 
broad range of cell surface virulence factors implicated in pathogenesis during infections. 
The expression of these virulence factors is under the control of the accessory gene 
regulator composed of Agr A, B, C and D domains (138). RNA III, the effector RNA molecule 
of the Agr system governs the expression of multiple genes, typically high RNAIII expression 
results in reduced expression of cell surface proteins (115). 
Previous studies, in particular, paper II and paper III have focused on S. aureus exotoxin-
mediated virulence properties and its contribution towards tissue pathology. In this study 
(paper IV) the focus shifted to understand the role of Agr system a global virulence regulator 
of S. aureus in determining the virulence response profile. The reason for this is that we 
identified a single amino acid substitution in agrC was responsible for starkly different 
phenotypes, e.g.  a cytotoxic vs. persistent phenotype in genetically highly related ST22 
clones causing skin infections. 
4.4.1 Distinct phenotypical profiles of ST22 strains due to a single point mutation 
in agrC 
In paper I we found that strains belonging to ST22 type formed the dominant clone both 
among carriers and disease isolates making up 28% of the total strain collection. Also, our 
study in which we defined robust functional responses of community S. aureus strains with 
distinct toxin profiles (paper II) identified different phenotypic virulence profiles in PBMC 
exposed to strains from a different genetic background as well as within the same ST type, 
including ST22 strains. Here we focused on two ST22 MRSA skin infection isolates, M37 
isolated from a recurrent skin infection and PUNE08 from an acute skin and soft tissue 
infection which displayed identical virulence gene profile as determined by microarray 
analysis in paper I, and yet revealed starkly different phenotypic response profile in PBMC. 
M37 induced proliferation, whereas PUNE08 was cytotoxic towards PBMC (Figure 1A; 
paper IV). In paper II the difference in phenotypic response profile was linked to the Agr 
type, and considering the key regulatory effect of Agr system on virulence gene expression, 
sequence analysis of the whole Agr region was performed. Sequence analyses identified a 
single point mutation in agrC at nucleotide position 667 (amino acid position: 223) in strain 
M37, leading to an amino acid substitution from tyrosine (Y) to cysteine (C). Molecular 
modelling and biophysical studies on these point mutation identified that amino acid 
substitution in the AgrC (Y223C) affects the oligomeric assembly of AgrC due to aggregation 
in solution and leads to destabilization of AgrC-AgrA interaction (Figure 1F and 1G; paper 
IV). Furthermore to confirm that the observed phenotypic difference is linked to the point 
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mutation, allelic replacement mutants (Y223C and C223Y) were generated in M37 and 
PUNE08 strains (Figure 2A; paper IV). A distinct phenotypic switch was observed when the 
wild-type strains and their respective mutants were tested for their proliferative activity and 
cytotoxicity in different cell types (Figure 2C and 2D; paper IV). PUNE08 wt strain switched 
from cytotoxic to a proliferative phenotype in the mutant PUNE08 agrC-Y223C, whereas 
opposite responses were noted for M37 and its mutant.  
To test the impact of such a phenotypic switch due to the agrC mutation, for infection 
outcome a series of experiments including virulence gene expression measurement, 
infection of keratinocytes, infection of human organotypic skin tissue models as well as in 
vivo infection using a murine skin infection model, were performed. The results 
demonstrated that Tyrosine at AgrC223 induces a higher exotoxin expression profile resulting 
in an increased cytotoxicity and severe epithelial disruption and tissue damage in both in-
vitro and in vivo infection experiments. In contrast, strains harboring Cysteine at AgrC223 
demonstrated  upregulation of genes encoding cell surface virulence factors, resulting in an 
increased adherence to and internalization into keratinocytes, and caused negligible 
epithelial damage in vitro as well as in vivo (Figure 3, 4 and 6; paper IV). Taken together the 
results demonstrated that strains harboring Cysteine at AgrC223 showed characteristic 
features of a colonizing/persistent phenotype (241, 242), while the cytotoxic activity is 
dependent on Tyrosine at AgrC223. 
4.4.2 Cytotoxic vs persistence phenotype in a human 3D skin model 
During the infection process of keratinocytes or human 3D skin model cytotoxic strains 
induced upregulation of Caspase 1 and IL1β indicating inflammasome activation. In contrast, 
reduced caspase 1 and IL1β levels were observed in cells and tissue models infected with 
colonizing/persistent strains. The persistent strains showed greater co-localization with 
LAMP1 as well as LC3-positive autophagic compartments as compared to cytotoxic strains, 
thus differing from the cytotoxic strains in terms of its intracellular locality (Figure 5A-5J; 
paper IV). Persistent strains also induced significant induction of autophagy as compared to 
cytotoxic strains (Figure 5F and 5I; paper IV). Inflammasome activation is considered as one 
of the major mechanisms for S. aureus clearance in skin (166, 243) and recent studies have 
shown that autophagy induction has the capacity to consume the inflammasome 
components (244, 245). Along the same line, our data indicate that inflammasome-mediated 
protective host responses are less pronounced in infections from persistent strains as 
compared to cytotoxic strains. Previous studies have shown that a common feature of 
persistent S. aureus strains is resistance against antibiotics and antimicrobial peptides, such 
as LL37 which is abundantly expressed in the skin where it contributes towards the first line 
of defense against bacterial infections (246, 247). LL-37 was readily detectable in 
organotypic skin tissues infected with persistent M37 wt and PUNE08 agrC-Y223C strains, 
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but not in tissue infected with the cytotoxic strains PUNE08 and M37 agrC-C223Y, which is 
likely a consequence of the greater disruption of the tissue (Figure 15). Determination of 
minimum inhibitory concentrations (MIC) of LL-37 revealed that persistent M37 wt and 
PUNE08 agrC-Y223C strains were highly resistant against LL37 mediated killing as 
compared to the cytotoxic PUNE08 wt and M37 agrC-C223Y strains (Figure 15 and Figure 
6K; paper IV). The mechanism underlying this difference in susceptibility towards LL-37 has 
not yet been explored and warrants further studies.  
 
Figure 15: A) Relative mRNA expression of LL-37 during the 24 h skin tissue model infection. The 
data represent the mean values ± SD from three independent infections (n=3). (B) Representative 
graph showing the effect of LL-37 on S. aureus strains incubated with different concentrations as 
indicated. The data shows the percentage of initial inoculum determined by CFU analysis in relation to 
peptide-free control cultures.  
In conclusion, our study on ST22 S. aureus strains shows that natural AgrC variants with 
starkly different phenotypes exists. Similarly, clinical isolates exhibiting agr-defective 
phenotypes due to mutation or dysfunction of the Agr system have been reported to be 
beneficial for survival and persistence within the host (244, 248, 249) . Both AgrC and AgrA 
regions are identified as hot spots for mutations leading to dysfunction of the Agr system 
(250). Notably, G55R in AgrC and L181I amino acid substitutions are observed in CC30 and 
ST80 lineages respectively, which are found to contribute towards decreased virulence and 
increased colonization abilities in these strains (249, 251). However, the point mutation 
identified in this study has not been reported previously. We link this phenotype switch to a 
naturally occurring specific mutation of receptor histidine kinase AgrC. Our data show that 
cytotoxic strains elicited severe tissue pathology in both in vitro human skin tissue model as 
well as in vivo murine model. Similarly, persistent intercellular strains can exploit the 
phagolysosome and autophagy compartments for their intercellular survival (Figure 16).The 
phenotypic switch to a persistent clone is inherently associated with resistance to 
antimicrobials, which will starkly reduce the antibiotic treatment efficacy. Whether this 
phenotypic switch represents a mechanism that provide a reservoir for dissemination and 
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become difficult to eradicate seems likely but remains to be proven. Similarly, the clinical 
relevance of strains with persistent phenotype causing recurrent skin infection, while 
cytotoxic strains causing acute skin infections needs to be addressed using a larger cohort 
of well-defined strains with appropriate clinical data on patients.  
 
Figure 16: Schematic presentations of the results in paper IV. 
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5 CONCLUDING REMARKS AND FUTURE ASPECTS 
S. aureus represents a significant health threat in both developing and developed countries. 
The incidences of these infections are rising, and unusually severe pathological signs are 
associated with certain S. aureus strains. Here we use clinical isolates with identical or 
related genetic background but with varying toxin profiles in clinically relevant human cell 
and tissue model systems to increase our understanding of the role of specific 
staphylococcal toxins in the pathologic events leading to the destructive infections in lung 
and skin. 
Paper I 
 Indian S. aureus strains were highly diverse and heterogeneous with all major clonal 
complexes circulating in the population. 
 The majority of the isolates were positive for PVL and egc genes along with 
combination of many other virulence factors 
The probability of MSSA conversion to MRSA is high in India due to rampant consumption of 
antibiotics. There lies a possibility of PVL positive MSSA strains acquiring SCCmec element 
to become PVL positive MRSA resulting in emergence of new variants. Hence prospective 
active surveillance studies including detailed molecular characterization of larger strain 
collections need to be conducted. 
Paper II 
 Community S. aureus isolates reveal robust functional response profiles, either 
proliferative or cytotoxic, in PBMC. 
 High α-toxin levels correlate with the cytotoxicity against PBMC demonstrating the 
importance of assessing concentrations and not solely presence of genes. 
 Significant association between proliferative or cytotoxic profiles and agr type 
The clinical relevance of these distinct functional profiles remains to be shown, as well as 
whether these phenotypic response profiles reflect specific pathotypes contributing to 
specific disease manifestation needs to be addressed. Another unexplored question is to 
understand the significance of expression levels and combined effects of superantigens and 
cytotoxins systemically as well as locally. 
Paper III 
 Severe lung tissue pathology is associated with high levels of both α-toxin and PVL 
 Both α-toxin and PVL were found to elicit strong upregulation of chemokines in the 
lung epithelium which resulted in increased neutrophil chemotaxis 
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 Data demonstrate a dual role for the toxins involving both cytolytic and chemotactic 
responses and underscore the importance of targeting multiple toxins and 
inflammatory pathways in the treatment of severe S. aureus pneumonia. 
The human 3D lung tissue model represents a powerful tool allowing for detailed studies of 
host-pathogen interactions and testing of novel intervention studies in a human tissue like 
setting. Further optimization of the tissue model to include innate immune cells during 
relatively long-term infection studies to understand the adaptation, spatial distribution of the 
bacteria and the host factors during pathological events needs to be explored. 
Paper IV 
 Naturally occurring single amino acid variant at AgrC223 of ST22 MRSA strains 
determines cytotoxic or persistence virulence phenotypes 
 Y223C substitution causes aggregation and destabilization of AgrC-AgrA interaction 
 High cytotoxicity,  induced inflammasome activation, and severe skin pathology is 
linked  to Tyrosine in AgrC223 
 Cysteine in AgrC223 determines a persistence phenotype with limited tissue 
pathology, but enhanced exploitation of autophagy and increased resistance to LL-
37 
The phenotypic switch may represent a mechanism for which new variants emerge and 
may contribute to the ongoing persistence of particularly successful clones, such as the 
ST22; however, this remains to be proven. Although we provide molecular and 
biochemical data on specific mutation leading to a diverse signaling capacity, differential 
virulence gene profiles and different infection outcome, the triggers driving these events 
are unclear. Further studies to identify if this mechanism is evolutionary occurring and 
actively driven by S. aureus or caused by the human host immune compartments 
warrant further investigations.  
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